Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common after antibiotic therapy. Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, respectively.
T h e ne w e ngl a nd jou r na l o f m e dicine I n high-income countries, Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients.
1,2 After completing initial antibiotic therapy, up to 35% of patients have recurrent C. difficile infection, 3, 4 which is more difficult to treat and is associated with more hospitalizations, more severe outcomes, and higher costs than the first infection and a 50 to 60% chance of repeat recurrent infections. 5, 6 Currently, no therapy has been approved to prevent recurrent C. difficile infection.
Passive or active immunization against C. difficile toxins A and B is protective in animals that are challenged with toxigenic C. difficile, [7] [8] [9] which underscores the key importance of the toxins in causing the symptoms of C. difficile infection. The relative biologic importance of toxins A and B in C. difficile infection is controversial, but it may be host species-dependent. [10] [11] [12] Neutralization of both toxins appears to be necessary for maximal protection in rodents, but neutralization of toxin B alone appears to be sufficient in piglets. 13 In humans, the level of circulating antibodies against toxin A 14, 15 or toxin B 16 has been correlated with protection against primary and recurrent C. difficile infection.
A new approach to the prevention of recurrent C. difficile infection is the administration of monoclonal antibodies against C. difficile toxins (in addition to antibiotic therapy) as a form of passive immunity. Actoxumab (MK-3415/GS-CDA1/ CDA1) and bezlotoxumab (MK-6072/MDX-1388/ CDB1) are fully human monoclonal antibodies that bind and neutralize C. difficile toxins A and B, respectively. In patients who were receiving metronidazole or vancomycin for C. difficile infection, a single intravenous infusion of actoxumabbezlotoxumab was found to be associated with a significantly lower rate of recurrent infection than placebo (7% [7 of 101] vs. 25% [25 of 99] , P<0.001), 17 whereas adjunctive treatment with actoxumab alone was not. 16 In two global, phase 3 trials, we examined the safety and efficacy of bezlotoxumab, both alone and combined with actoxumab, for the prevention of recurrent C. difficile infection.
Me thods

Trial Oversight
MODIFY I and MODIFY II were randomized, double-blind, placebo-controlled trials conducted at 322 sites in 30 countries from November 1, 2011, through May 22, 2015 . Both trials were conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. The protocols and amendments were approved by the institutional review board or independent ethics committee at each study site. Written informed consent was obtained from all participants before the trial began. The MODIFY I and MODIFY II trials were designed by representatives of Merck and by academic advisors. All the data were collected by investigators and associated site personnel, analyzed by Merck statisticians, and interpreted by the authors. The first, second, and last authors wrote the first draft of the manuscript with the assistance of a medical writer who is an employee of Merck. All the authors participated in reviewing and editing the manuscript, approved the submitted versions, had full access to the data (under confidentiality agreements), and vouch for the accuracy and completeness of the data and for the fidelity of the trials to the protocols, which are available with the full text of this article at NEJM.org.
Participants and Procedures
The participants were adults with primary or recurrent C. difficile infection who were receiving oral standard-of-care antibiotics (metronidazole, vancomycin, or fidaxomicin, chosen by the treating physician) for 10 to 14 days. Participants who were receiving oral vancomycin or fidaxomicin could also receive intravenous metronidazole. C. difficile infection was defined as diarrhea (≥3 unformed bowel movements [types 5 to 7 on the Bristol stool scale 18 ] in 24 hours) with a stool test result that was positive for toxigenic C. difficile. The diagnostic methods included cytotoxicity assays, culture with toxin detection or strain typing, and commercial assays that detect (at least) toxin B or its gene (see the Supplementary Appendix, available at NEJM.org). Microbiologic assessments were performed at R.M. Alden Research Laboratory. Polymerase-chain-reaction ribotyping of C. difficile cultures was completed at Leeds Teaching Hospitals. 19 Detailed inclusion and exclusion criteria are provided in the trial protocols.
Participants were randomly assigned in a 1:1:1:1 ratio to receive a single dose of bezlotoxumab (10 mg per kilogram of body weight), actoxumab plus bezlotoxumab (10 mg per kilogram each), placebo (0.9% saline), or, in MODIFY I A Quick Take is available at NEJM.org only, actoxumab alone (10 mg per kilogram); actoxumab was not evaluated alone in MODIFY II because earlier results suggested a lack of efficacy for this antibody. 16 The use of a single dose was supported by the long half-life of the monoclonal antibodies (approximately 19 days). Randomization was stratified according to oral standard-of-care antibiotic and hospitalization status (inpatient or outpatient). The participants, investigators, study-center personnel (except the pharmacist preparing the infusion), and sponsor personnel were unaware of the study-group assignments until the trial was completed and the database was locked.
Participants who underwent randomization received a single, 60-minute intravenous infusion of the assigned monoclonal antibody or placebo (study day 1) while they were receiving standardof-care antibiotic therapy (in three cases, standardof-care therapy was initiated on the day after the infusion). Participants recorded unformed bowel movements daily until day 80 to 90 after the infusion; new episodes of diarrhea were monitored through telephone contact between visits. Safety assessments included preinfusion and postinfusion electrocardiography, monitoring for reactions for 24 hours after infusion, recording of all adverse events and results of laboratory tests through week 4, and recording of serious adverse events (including deaths) through week 12.
Both trials had a planned sample size of 400 participants per group. Efficacy was assessed in a modified intention-to-treat population, which included all randomly assigned participants who received the study infusion, had a baseline stool test that was positive for toxigenic C. difficile, and began receiving standard-of-care therapy before or within 1 day after receiving the monoclonal antibodies. Safety was assessed in the as-treated population, which included all randomly assigned participants who received the study infusion, analyzed according to the actual treatment received.
Prespecified End Points
The primary end point was the proportion of participants with recurrent C. difficile infection (defined as a new episode of C. difficile infection after initial clinical cure of the baseline episode) during 12 weeks of follow-up in the modified intention-to-treat population (for the rationale for using this end point, see the Statistical Analysis Methods section in the Supplementary Appendix). Initial clinical cure (defined as no diarrhea for 2 consecutive days after completion of standard-of-care antibiotic therapy administered for ≤16 days) was an exploratory end point. Secondary analyses included the rate of recurrent C. difficile infection in the subgroup of participants in the modified intention-to-treat population who had an initial clinical cure, as well as in prespecified subgroups of participants with risk factors for recurrent C. difficile infection or for adverse outcomes related to C. difficile infection: an age of 65 years or older, 20,21 a history of C. difficile infection, 3, 4 compromised immunity, 22, 23 clinically severe C. difficile infection (defined as a Zar score ≥2; scores range from 1 to 8, with higher scores indicating more severe infection), 24 and infection with a strain associated with poor outcomes (strain 027, 20,25-27 078, 28 or 244 29, 30 ). A secondary end point was the rate of sustained cure (i.e., initial clinical cure of the baseline episode of C. difficile infection and no recurrent infection through 12 weeks), also known as global cure or sustained clinical response. The time to recurrent infection and the rate of recurrence of diarrhea (defined as a new diarrheal episode, regardless of whether it was associated with toxigenic C. difficile) were exploratory end points. The prespecified and post hoc efficacy end points are listed in Table S1 in the Supplementary Appendix.
Statistical Analysis
MODIFY I and MODIFY II were independent and nearly identical trials, each of which was powered to determine the efficacy of bezlotoxumab alone or in combination with actoxumab for prevention of recurrent C. difficile infection. MODIFY I had an adaptive design in which discontinuation of enrollment in the actoxumab group, bezlotoxumab group, or both was allowed if a significant difference in the rate of recurrent infection between either of these groups and the actoxumab-bezlotoxumab group was found in an interim analysis. In the interim analysis, which was prepared and reviewed by an independent data and safety monitoring committee and included 632 participants in the modified intentionto-treat population (39.5% of the 1600 planned), the rate of recurrent infection was found to be significantly higher in the actoxumab group than in the actoxumab-bezlotoxumab group (P = 0.02), and more deaths and serious adverse events were found to have occurred in the actoxumab group T h e ne w e ngl a nd jou r na l o f m e dicine than in the placebo group. Enrollment in the actoxumab group was therefore stopped.
The protocols of both trials were designed to strongly limit the study-wise type I error rate to 5% for the primary end point. The multiplicity strategy addressed multiple comparisons among the study groups in both trials and multiple analysis times in MODIFY I (see the protocols). Comparisons between treatment and placebo with regard to the primary end point were performed at a two-sided alpha level of 0.025 in MODIFY I (because of the more complex multiplicity strategy) and at a two-sided alpha level of 0.050 in MODIFY II. Both trials had more than 90% power to detect a difference of 9 to 10 percentage points in the rate of recurrent infection, under the assumption of a rate of 20% in the placebo group.
A planned analysis of pooled data from the two trials was documented in an integrated statistical analysis plan (see the protocol). Pooling the data also facilitated the analysis of treatment effects in important prespecified subgroups of participants who were at high risk for recurrent C. difficile infection or for adverse outcomes related to C. difficile infection. Additional details regarding statistical methods, including sensitivity analyses and approaches to handling missing data, are provided in the Supplementary Appendix.
R esult s
Study Population
Of the 2655 participants who underwent randomization in the trials, 2580 (97%) were treated and 2559 (96%) were included in the modified intention-to-treat population ( The median age of participants in the modified intention-to-treat population was 66 years (range, 18 to 100); 86% were white, and 56% were women. Key baseline characteristics were balanced among the study groups (Table 1, and   Tables S2 and S3 in the Supplementary Appendix). Most participants were inpatients (68%), and most received either metronidazole (47%) or vancomycin (48%) as the oral standard-of-care antibiotic; only 4% received fidaxomicin. In 94% of the participants, the study agent was infused within 6 days after initiation of standard-of-care antibiotic treatment (median, 3 days in all groups) ( Table S4 in (Table S5 in the Supplementary Appendix).
Recurrence of C. difficile Infection
In both trials, the percentage of participants in the modified intention-to-treat population who had recurrent infection ( Fig. 1 * Severe infection was defined as a Zar score of 2 or higher. The Zar score ranges from 1 to 8 and is based on the following factors: age greater than 60 years (1 point), body temperature higher than 38.3°C (100°F) (1 point), albumin level lower than 2.5 g per deciliter (1 point), peripheral white-cell count higher than 15,000 per cubic millimeter within 48 hours (1 point), endoscopic evidence of pseudomembranous colitis (2 points), and treatment in an intensive care unit (2 points). † The determination of whether a participant was immunocompromised was made on the basis of medical history or use of immunosuppressive therapy. ‡ Included are systemic antibiotics other than the standard-of-care antibiotic that was given to treat C. difficile infection. § Renal impairment was defined as a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or higher. ¶ Hepatic impairment was defined as having two or more of the following: an albumin level of 3.1 g per deciliter or lower, an alanine aminotransferase level at least 2 times the upper limit of the normal range, a total bilirubin level at least 1.3 times the upper limit of the normal range, or mild, moderate, or severe liver disease (as reported on the Charlson Index). ‖ Africa includes South Africa; Asia-Pacific includes Australia, Japan, Korea, New Zealand, and Taiwan; Latin America includes Argentina, Brazil, Chile, Colombia, and Mexico; Europe includes Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Israel, Italy, Poland, Portugal, Russia, Spain, Sweden, Switzerland, Turkey, and the United Kingdom; and North America includes Canada and the United States. ** The most common strains were ribotypes 027, 014, 002, 001, 106, and 020. † † The denominators used to calculate percentages are the numbers of participants who had a positive culture. tween the actoxumab group and the placebo group in MODIFY I (26% [60 of 232] and 28% [109 of 395], respectively; P = 0.64). Bezlotoxumab and actoxumab-bezlotoxumab were similar in their effect on the rate of recurrent infection, with no significant difference found between these groups in either trial (Table S6 in the Supplementary Appendix).
In the subgroup of participants in the modified intention-to-treat population who had initial clinical cure, the differences in the rate of recurrent infection were similar to those found in the overall modified intention-to-treat population, both with respect to the rates in the bez- Table S7 in the Supplementary Appendix). Sensitivity analyses addressing the effect of the initial clinical cure rate and the effect of missing or incomplete data (including early discontinuations due to death or other reasons) on the rate of recurrent infection were consistent with the results of the primary analysis (see the Supplementary Appendix).
The distribution of the time to recurrent infection according to study group is shown in Figure 2 . Most recurrences (71%) occurred within 4 weeks after study infusion. Differences in the rate of recurrent infection between either regimen that included bezlotoxumab and placebo were apparent as early as 2 weeks after infusion and were maintained through week 12. The absolute differences in the Kaplan-Meier rates of recurrent infection between the bezlotoxumab group and the placebo group were 12 percentage points at week 4, 12 percentage points at week 8, and 13 percentage points at week 12; the corresponding differences between the actoxumabbezlotoxumab group and the placebo group were 11, 12, and 13 percentage points. The results shown are for the modified intention-to-treat population, which included all randomly assigned participants who received the study infusion, had a baseline stool test that was positive for toxigenic C. difficile, and started receiving standard-of-care therapy before or within 1 day after receiving the monoclonal antibodies. P values were calculated by the Miettinen and Nurminen method, with stratification according to trial, standard-of-care therapy, and hospitalization status. 16 Across prespecified subpopulations of participants who were at high risk for recurrent C. difficile infection or for adverse outcomes related to C. difficile infection, the rates of recurrent infection were lower in the bezlotoxumab group and in the actoxumab-bezlotoxumab group than in the placebo group, both in the pooled data set (Fig. 3 ) and in the individual trials (Figs. S3 and S4 in the Supplementary Appendix). The observed effects on the rate of recurrent infection were similar with bezlotoxumab and actoxumabbezlotoxumab in all subgroups except participants with infection caused by C. difficile strain 027 and participants with infection caused by strain 027, 078, or 244. Among participants with one or more risk factors (1964 of 2559, 77%), recurrent infection occurred in 17% of the participants (100 of 592) in the bezlotoxumab group, in 16% of the participants (99 of 606) in the actoxumab-bezlotoxumab group, and in 30% of the participants (174 of 583) in the placebo group (post hoc analysis). In a comparison of participants according to hospitalization status, standardof-care antibiotic therapy, and geographic region, The results shown are for the modified intention-to-treat population with data pooled from the two trials. Shown at the bottom of the graph are the numbers of participants who were at risk at the start of the interval and the KaplanMeier rates and 95% confidence intervals at each time point. Data from participants who did not have initial clinical cure were right-censored at day 1 (the day of the infusion). Data from participants who completed the 12-week study period without documented recurrent infection were censored at the date of the last completed stool count. For participants who discontinued before recurrent infection, the time to event was considered to be right-censored at the date of the last stool record. The inset shows the same data on an expanded y axis. T h e ne w e ngl a nd jou r na l o f m e dicine the differences in the rates of recurrent infection were consistent with those seen overall (Fig. 3) . Specifically, the choice of standard-of-care antibiotic (metronidazole, vancomycin, or fidaxomicin) had no discernible effect on the efficacy of bezlotoxumab (see the Supplementary Appendix). 
Weeks after Infusion
no./total no. (%)
Bezlotoxumab for Recurrent C. difficile Infection
Sustained Cure and Recurrence of Diarrhea
In MODIFY I, sustained cure was achieved in 60% of the participants (232 of 386) in the bezlotoxumab group and in 59% of the participants (225 of 383) in the actoxumab-bezlotoxumab group, as compared with 55% of the participants (218 of 395) in the placebo group (difference between bezlotoxumab and placebo, 4.8 percentage points; 95% CI, −2.1 to 11.7; difference between actoxumab-bezlotoxumab and placebo, 3.5 percentage points; 95% CI, −3.5 to 10.4). In MODIFY II, sustained cure was achieved in 67% (264 of 395) of bezlotoxumab recipients and in 57% (224 of 390) of actoxumab-bezlotoxumab recipients, as compared with 52% (197 of 378) of placebo recipients (difference between bezlotoxumab and placebo, 14.6 percentage points; 95% CI, 7.7 to 21.4; P<0.001; difference between actoxumab-bezlotoxumab and placebo, 5.2 percentage points; 95% CI, −1.8 to 12.2). In the pooled data set, the rate of sustained cure was 64% (496 of 781) with bezlotoxumab, 58% (449 of 773) with actoxumab-bezlotoxumab, and 54% (415 of 773) with placebo ( Fig. S5 and Table S8 in the Supplementary Appendix). Diarrhea recurrence, irrespective of an association with C. difficile infection, was an exploratory end point. As expected, the rates of diarrhea recurrence were higher than the rates of C. difficile infection recurrence; however, the treatment effects observed in association with each study agent with regard to the primary end point were maintained (Table S9 in the Supplementary Appendix).
Safety
Adverse events are summarized in Table 2 . Infusion-specific reactions were reported by 9% of the participants; the most frequent reactions were nausea (2%), headache (2%), dizziness (1%), fatigue (1%), and pyrexia (1%), with similar rates across the study groups (Table S10 in the Supplementary Appendix). Infusion-specific reactions were rated as mild (76%) or moderate (22%) and resolved within 24 hours. Study infusion was discontinued because of an adverse event in 2 participants (1 in the bezlotoxumab group and 1 in the actoxumab group). During the 4 weeks after infusion, the overall rates of adverse events were similar with bezlotoxumab (62%), actoxumabbezlotoxumab (59%), and placebo (61%) and were higher with actoxumab (67%). Rates of serious adverse events and deaths were also higher in the actoxumab group than in the other study groups. Drug-related adverse events occurred in 7% of the participants (172 of 2579), and serious drugrelated adverse events in 1% (14 of 2579), and both occurred at similar rates across the study groups. The adverse events reported by 4% or more of participants in any study group were abdominal pain, diarrhea, nausea, vomiting, fatigue, pyrexia, C. difficile infection, urinary-tract infection, and headache. The most common fatal adverse events were related to infections and infestations, which occurred in 11 participants (1%) in the actoxumab-bezlotoxumab group, 11 participants (1%) in the bezlotoxumab group, 11 (5%) participants in the actoxumab group, and 25 participants (3%) in the placebo group; the next most common type of fatal adverse event was cardiac disorders, which occurred in 8 (1%), 14 (2%), 2 (1%), and 12 (2%) participants, respectively (Table S11 in the Supplementary Appendix). No binding or neutralizing antidrug antibodies to bezlotoxumab were detected after treatment with bezlotoxumab or actoxumab-bezlotoxumab (see the Supplementary Appendix).
Discussion
The results of MODIFY I and MODIFY II, separately and combined, show that among participants receiving standard-of-care antibiotic therapy for primary or recurrent C. difficile infection, bezlotoxumab was associated with a significantly lower rate of recurrent infection than was placebo. Both the rates of recurrent infection The results shown are for recurrence of C. difficile infection (CDI) in the modified intention-to-treat population, with data pooled from the two trials. Panel A shows the subgroup results for bezlotoxumab versus placebo; Panel B shows the subgroup results for actoxumabbezlotoxumab versus placebo. The absolute differences between rates (expressed as percentage points) and 95% confidence intervals for active treatment versus placebo were calculated by the Miettinen and Nurminen method without stratification. The Zar score ranges from 1 to 8 and is based on the following factors: age greater than 60 years (1 point), body temperature higher than 38.3°C (100°F) (1 point), albumin level lower than 2.5 g per deciliter (1 point), peripheral white-cell count higher than 15,000 per cubic millimeter within 48 hours (1 point), endoscopic evidence of pseudomembranous colitis (2 points), and treatment in an intensive care unit (2 points).
T h e ne w e ngl a nd jou r na l o f m e dicine and the absolute differences in the rates of recurrent infection among the study groups were consistent between the two trials. Bezlotoxumab was associated with a rate of recurrent infection that was 38% (10 percentage points) lower than that associated with standard-of-care therapy alone. Actoxumab was not efficacious when given alone and provided no additional benefit when given with bezlotoxumab. These observations are consistent with evidence indicating that toxin B is the main determinant of virulence in recurrent C. difficile infection in humans, 10-13 but they do not exclude the possibility that toxin A is also a contributing factor and that anti-toxin A antibodies are protective in human disease, as is suggested by seroepidemiologic data. 14, 15 The effect of bezlotoxumab in preventing recurrent C. difficile infection was sustained throughout 12 weeks. We note that 29% of recurrent infections occurred beyond the conventional Death 51 (6.6) 56 (7.1) 27 (11.5) 59 (7.6) * The adverse events reported on the day of or day after infusion that might have been a sign of an acute hypersensitivity reaction were nausea, vomiting, chills, fatigue, feeling hot, infusion-site conditions, pyrexia, arthralgia, myalgia, dizziness, headache, dyspnea, nasal congestion, pruritus, rash, urticaria, flushing, hot flush, hypertension, and hypotension. † Causality was assessed by the investigator, who was unaware of the study-group assignments. ‡ A list of serious drug-related events is provided in Table S12 in the Supplementary Appendix. § This category includes events with an incidence of at least 4% in at least one study group reported during the first 4 weeks after infusion. ¶ C. difficile infection (the primary efficacy end point) was to be reported as an adverse event only if it was serious. ‖ A summary of serious adverse events is provided in Table S13 in the Supplementary Appendix. 4-week assessment period for treatment efficacy. The number needed to treat to prevent one episode of recurrent C. difficile infection was 10; it was 6 among participants 65 years of age or older and those with previous C. difficile infection.
Our trials included a substantial percentage of participants (77%) who had one or more risk factors for recurrent C. difficile infection or for adverse outcomes related to C. difficile infection; bezlotoxumab was consistently associated with rates of recurrent infection that were lower than those associated with placebo across these subgroups. In the largest subgroup (persons ≥65 years of age), bezlotoxumab was associated with a rate of recurrent infection that was 51% lower than that associated with placebo. Among participants who were infected with the 027 strain, actoxumab-bezlotoxumab was found to have a larger treatment effect than bezlotoxumab alone. However, given the relatively small number of participants, it is not clear whether this difference was due to a true advantage of actoxumabbezlotoxumab over bezlotoxumab alone.
A single intravenous dose of bezlotoxumab at 10 mg per kilogram, given alone or in combination with actoxumab, had a generally favorable safety profile in adults who were receiving standard-of-care antibiotic therapy. The rates of adverse events were generally as expected, given the underlying disease severity, baseline coexisting conditions, and ages of the participants. The reasons that higher rates of death and serious adverse events were found in the actoxumab group are unclear. The conditions associated with death in this group (including sepsis, which was present in approximately 25% of those who died) also occurred in the other groups. The rates of death and serious adverse events in the actoxumab-bezlotoxumab group were similar to those in the placebo group and the bezlotoxumab group. In light of the advanced age and coexisting conditions of the participants who died, a causal association between actoxumab treatment and death could not be established or ruled out.
A lower rate of initial clinical cure in the bezlotoxumab group than in the placebo group was found in MODIFY I, but the reverse was found in MODIFY II (by a similar magnitude). The differences in the rate of initial clinical cure between these two groups in each trial were small and not clinically meaningful. Furthermore, the observed rate of initial clinical cure in the pooled data from the two trials was the same (80%) for these two groups, a finding consistent with the a priori expectation that bezlotoxumab does not affect the efficacy of standard-of-care antibiotic treatment. Toxin B levels in stool are markedly reduced early after the start of standard-of-care antibiotic therapy; therefore, bezlotoxumab would not be expected to affect initial clinical cure, since most participants received the antitoxin 3 or more days after standard-of-care antibiotic therapy began. 31, 32 The results from each trial regarding the rate of recurrent C. difficile infection significantly favored bezlotoxumab when either the modified intention-to-treat population or the subgroup with initial clinical cure was used as the denominator. The advantage in the rate of sustained cure associated with bezlotoxumab was smaller in MODIFY I than in MODIFY II and did not reach significance in MODIFY I because of the smaller difference in observed initial clinical cure rates between the bezlotoxumab group and the placebo group in that trial.
These trials had several limitations. First, the selection of standard-of-care antibiotic was not standardized but rather was at the discretion of the investigator. To control for this, the study groups were stratified according to the standardof-care antibiotic and therefore were balanced with regard to that variable. Moreover, the efficacy of bezlotoxumab with regard to the rate of recurrent infection was not affected by the choice of standard-of-care antibiotic. Second, although the time of study infusion relative to the onset of symptoms was balanced across treatment groups, the time interval was broad; thus, an assessment of the effect of neutralization of toxin B or toxin A on the severity and duration of the baseline episode could not be performed. Third, the proportion of participants with a severe baseline episode of C. difficile infection is probably an underestimate, since more than 90% of participants were receiving standard-of-care antibiotics when the severity assessment was performed. Fourth, other therapies that are currently used for the prevention of recurrent C. difficile infection were not allowed; therefore, the combined effect of bezlotoxumab and other approaches (e.g., fecal microbiota transplantation) is not known. Finally, safety assessments were limited because of the relatively small number of patients who received bezlotoxumab, which makes it difficult to detect potentially serious but lowfrequency toxic effects.
In summary, a single intravenous dose of bezlotoxumab against C. difficile toxin B, when given with standard-of-care antibiotics, provided protection against recurrent C. difficile infection for up to 12 weeks that was superior to that provided by treatment with standard-of-care antibiotics alone. Bezlotoxumab has a novel mechanism of action that reduces the likelihood of recurrent C. difficile infection, most notably among patients who have an increased risk of this unfavorable outcome.
